Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by Stars-Alignedon May 02, 2016 10:21am
102 Views
Post# 24832352

Drug increase costs might be planned

Drug increase costs might be planned
there is an idea floating around that this increase could actually save the business, Ackman knew that the business was failing years ago and could have set out a plan to revitalize. By increasing their drug prices by over 200% meant more revenue with same opearting margin. They have been doing this for Months. Reporting using NON GAPP metrics would actually alow them to disclose of this money in many s different ways. This could get interstitial g and all could be plan to keep these prices up high as long as possible to bring this company on top.
<< Previous
Bullboard Posts
Next >>